Aktuellt
SENASTE
The independent Data Monitoring Committee (DMC) recommends to proceed the clinical Tumorad-01, with inclusion of patients with different tumor types. This green light follows as the first three treated patients in the study shows a satisfactory safety profile. The next DMC meeting will follow once three additional patients have completed the first treatment cycle.
LÄS MER
